Tuesday, October 4, 2022

561.316.3330

Biotechnology News Magazine

Palette Life Sciences Announces the Establishment of a Wholly Owned Subsidiary in Japan

Expansion will allow for Palette Life Sciences to provide better support to healthcare providers in Japanese market

Latest Posts

Sonrava Health to Include the PreTRM® Test in Its Employee Maternity Benefits Package in Collaboration with Cerebrae and Sera Prognostics

Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and...

BRAINBox Solutions Announces New U.S. Patent Allowance, Strengthening Biomarker Portfolio for Multi-Modal Mild Traumatic Brain Injury Test

BRAINBox Solutions notes the new patent covers both diagnosis of TBI and patient monitoring post-injury, particularly for determining return to work or play.

New Initiative Brings Leading Life Sciences Companies Together To Drive Collective Impact in Awareness, Diagnosis, Care, and Health Equity for Patients with Amyloidosis

Despite notable progress in recent years, amyloidosis patients continue to experience high unmet needs and gaps in treatment and support.

GBS Inc. Acquires Intelligent Fingerprinting Limited and its Proprietary Drugs of Abuse Screening Technology

Steven Boyages, CEO of GBS Inc. stated, “We believe this acquisition generates significant value for our shareholders, and I am extremely excited to be on the forefront of this transition. Bringing IFP under the GBS umbrella marks a significant advancement toward achieving our strategic goals of improving patients’ lives outside of saliva-based glucose testing and laying the pathway in becoming a leader in the development of rapid, non-invasive diagnostic solutions. We remain excited to accelerate our strategy and revenue growth through this collaboration with IFP.”

Palette Life Sciences, a fully integrated global life sciences company dedicated to improving patient outcomes, today announced the establishment of a wholly owned subsidiary located in Tokyo, Japan to commercialize Palette’s portfolio of medical products.

As of January 1, 2022, Palette Life Sciences Japan K.K. has been cleared to distribute Deflux® directly to customers throughout the country. In addition, Palette Life Sciences is working to expand its Japanese offering, actively pursuing regulatory clearance for its Barrigel® and Solesta® brands.

Prior to establishing the subsidiary, Palette Life Sciences partnered with local distributors in Japan to provide access to Deflux. Direct representation of Palette’s products in the country will provide enhanced opportunities to better support local physicians through training, education, and practice support.

“Palette Life Sciences has been rapidly expanding its footprint into new markets over the last several years, including Europe, LATAM, Middle East, Australia and now Japan. This new subsidiary enables local Palette experts to directly support healthcare providers and better service the network of organizations using our products throughout the country. We are excited to be making this long-term commitment to the Japanese market,” said Ole Mikkelsen, Chief Operating Officer, Palette Life Sciences.

Palette Life Sciences Japan shipped its first direct orders of Deflux® in early January. Deflux® is the minimally invasive, first-line treatment for vesicoureteral reflux (VUR), a malformation of the ureteral tunnel in the bladder affecting 1% of children worldwide. All of Palette Life Sciences’ products leverage their global rights to Non-Animal Stabilized Hyaluronic Acid (NASHA®), a proprietary hyaluronic acid formulation that has been proven safe and effective and used for more than 20 years in over 50 million medical procedures worldwide.[1]

“It is exciting and a great opportunity to start Palette Life Sciences Japan K.K. to deliver Palette’s product directly to patients and physicians. We will be able to communicate closely with our customers and promote our products very effectively. It will also connect Japan with global resources to provide consistent training and educational support,” said Yoshiki Kawabata, General Manager, Palette Life Sciences Japan.

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine